Related Experiment Video
Updated: Feb 1, 2026

Colorectal Cancer Cell Surface Protein Profiling Using an Antibody Microarray and Fluorescence Multiplexing
Published on: September 25, 2011
Significant antitumor effect of an antibody against TMEM180, a new colorectal cancer-specific molecule
Masahiro Yasunaga1, Shinji Saijou1, Shingo Hanaoka1
1Division of Developmental Therapeutics, Exploratory Oncology Research & Clinical Trial Centre, National Cancer Centre, Kashiwa, Japan.
Abstract:
The present state of therapy for colorectal cancer (CRC) is far from satisfactory, highlighting the need for new targets for this disease. We identified a new CRC-specific molecule, TMEM180, a predicted 11-pass transmembrane protein that apparently functions as a cation symporter. We developed an anti-TMEM180 mAb and then succeeded in humanizing the mAb. Immunohistochemistry (IHC) in CRC with the mAb showed a similar positivity rate as compared with anti-epidermal growth factor receptor mAb, and IHC with anti-TMEM180 mAb did not show staining in major organs used in this study. Immune electron microscopy clearly indicated that TMEM180 was present on the tumor exosome. The TMEM180 promoter region contains 10 hypoxia-responsive element consensus sequences; accordingly, SW480 cells upregulated TMEM180 under low-oxygen conditions. Anti-TMEM180 mAb has in vitro antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity activity, and SW480 CRC xenografts were eradicated by the mAb. These data indicate that TMEM180 may be a new CRC marker and that a mAb against this protein could be used as antibody-based therapy against CRC.
Insights
Researchers discovered TMEM180, a novel colorectal cancer (CRC) target. An antibody targeting TMEM180 shows promise for CRC diagnosis and antibody-based therapy, eradicating tumors in preclinical models.
Area of Science:
- Oncology
- Molecular Biology
- Immunology
Background:
- Current colorectal cancer (CRC) therapies are insufficient, necessitating novel therapeutic targets.
- TMEM180, an 11-pass transmembrane protein functioning as a cation symporter, has been identified as a CRC-specific molecule.
Purpose of the Study:
- To investigate TMEM180 as a potential diagnostic marker and therapeutic target for colorectal cancer.
- To develop and characterize an anti-TMEM180 monoclonal antibody (mAb) for CRC treatment.
Main Methods:
- Development and humanization of an anti-TMEM180 mAb.
- Immunohistochemistry (IHC) to assess TMEM180 expression in CRC tissues and normal organs.
- Immune electron microscopy to localize TMEM180 on tumor exosomes.
- Assessment of TMEM180 upregulation under hypoxic conditions.
- Evaluation of in vitro antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC).
- In vivo efficacy study using SW480 CRC xenografts.
Main Results:
- TMEM180 is specifically expressed in CRC with minimal staining in major organs.
- TMEM180 is localized on tumor exosomes and its expression is upregulated under hypoxia.
- The anti-TMEM180 mAb demonstrated significant in vitro cytotoxic activity (ADCC and CDC).
- SW480 CRC xenografts were eradicated by the anti-TMEM180 mAb treatment.
Conclusions:
- TMEM180 represents a promising new biomarker for colorectal cancer.
- An antibody targeting TMEM180 holds potential for novel antibody-based CRC therapy.
Related Concept Videos
Molecules and Compounds
Antibody Structure
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...
Specific Heat
For example, increasing the temperature of one gram of water by 1°C requires one calorie of heat energy and can be written as 1 cal/g-°C, or...
Positive Regulator Molecules
Antibody Actions
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
Conservative Site-specific Recombination and Phase Variation
The recognition sites for Cre recombinase called LoxP...

